Fig. 3.

Association of PD-L1 expression detected by immunohistochemistry staining with survival outcomes. A Subgroup analyses of progression-free survival (PFS) in the entire population; B subgroup analyses of overall survival (OS) in the entire population; C PFS was longer in the PD-L1 positive group (n = 13) than in the PD-L1 negative group (n = 18) (P = 0.015); D Significantly longer overall survival was not observed in the group with positive PD-L1 expression (P = 0.31). ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; TNM, tumor node metastasis classification